Skip to main content Skip to main content
Go to homepage

Omaveloxolone for patients with mitochondrial myopathy

Omaveloxolone (RTA 408) for patients with mitochondrial myopathy


This study is closed.

For more information on this study, visit:

Who May Qualify?:

Male or female mitochondrial myopathy patients 18 through 75 years of age.

We will screen potential study participants for additional criteria.

Who Does Not Qualify:

For detailed information on qualifying for enrollment visit:

Study Status:
Study Sponsor:

Reata Pharmaceuticals, Inc.

Full IRB Study Title:
A Phase 2 Study of the Safety, Efficacy and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-5012

Lead Investigator
Bruce H. Cohen, MD, FAAN

Chair, NeuroDevelopmental Science Center; Philip H. Maynard Chair in NeuroDevelopmental Science Fund; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.